Lisa G. Horvath
The University of Sydney(AU)University of Sydney(AU)Garvan Institute of Medical Research(AU)Royal Prince Alfred Hospital(AU)UNSW Sydney(AU)Cooperative Trials Group for Neuro-Oncology(AU)Chris O’Brien Lifehouse(AU)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Cancer, Lipids, and Metabolism, Radiopharmaceutical Chemistry and Applications, Cancer Immunotherapy and Biomarkers, Epigenetics and DNA Methylation
Most-Cited Works
- → Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer(2019)1,551 cited
- → Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci(2018)994 cited
- → Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction(2021)484 cited
- → FAK signaling in human cancer as a target for therapeutics(2014)450 cited
- Frequent loss of estrogen receptor-beta expression in prostate cancer.(2001)
- → PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma(2015)301 cited
- → Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study